Combining Active And Passive DHT Monitoring To Accelerate Parkinson's Disease Drug Development

Despite a strong drug development pipeline for neurological conditions like Parkinson’s and Alzheimer’s disease, many therapies struggle to advance from Phase 2 to Phase 3 trials — raising an important question: are the therapies ineffective, or are current efficacy measurements too limited in sensitivity?

Digital health technologies offer a promising solution by enabling more accurate, real-world assessments of daily patient function, improving the sensitivity of outcome measures in neurology trials. In this Digital Health Monthly webinar, we explore a groundbreaking scientific collaboration between ActiGraph and Indivi that leverages both active and passive digital measures.

Together, these tools allow for the remote, continuous monitoring of motor and non-motor symptoms, providing a deeper, more nuanced understanding of patients’ capacity, perception, and performance — critical insights for evaluating complex neurological therapies. We also highlight the scientific, analytical, and operational foundations supporting this novel digital health solution, designed to optimize neurology clinical trials from start to finish.